MCE products for research use only. We do not sell to patients.

Taurocholic acid

MCE China：Taurocholic acid

Brand：MedChemExpress (MCE)

Cat. No.HY-B1788

CAS：81-24-3

Synonyms：Taurocholic Acid

Purity：99.64%

Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect.

In Vitro：Taurocholic acid (100 μM, 24 h) decreases the proportion of CD3+CD8+ T and NK cells in isolated PBMCs from HBeAg-positive CHB patients[2].Taurocholic acid (100 μM, 24 h) decreases IFN-α stimulated cytokine and cytotoxic granule levels (IFN-γ, TNF-α, granzyme B) in CD3+CD8+ T and NK cells[2].

In Vivo：Taurocholic acid can induce stress-induced gastric injury models[3]. .f12{ font-size: 12px; } .fwb{ font-weight: bold; } .lh22{ line-height: 22px;; } .lh23 { line-height: 23px; } .pl13{ padding-left: 13px;; } .part { margin-top: 18px; } .mold-first-tit { width: 100%; height: 44px; line-height: 44px; background: #F9F7FB; border-bottom: 1px solid #EBE4F6; padding-left: 16px; box-sizing: border-box; margin-bottom: 17px; } .mold-second-tit:before { content:""; width: 6px; height: 6px; display: inline-block; border-radius: 50%; background: rgba(255,102,0,0.4); margin-right: 12px; position: relative; top: -3px; } .lft-border { border-left: 1px dotted #EBE4F6; padding-right: 12px; margin-left: 3px; box-sizing: border-box; padding-bottom: 12px; } /* .part .dec:last-child { border-bottom: 0; } */ .dec { margin: 10px 15px 0; padding-bottom: 10px; border-bottom: 1px dashed #EBE4F6; } .btm-border { border-left: 1px dashed #EBE4F6; } .text-bg { margin-top: 10px; background: #FFFBF1; padding: 14px; border-bottom: 0; position: relative; } .text-note-bg { margin-top: 10px; background: #FFFDF7; padding: 12px; border-bottom: 0; position: relative; } .text-note { width: 51px; height: 20px; line-height: 20px; background: #FFE2AA; text-align: center; border-radius: 0 0 8px 0; position: absolute; top: 0; left: 0; } .text-note-dec { margin-top: 15px;; } Induction ofstress-induced gastric injury[3] Background Both in humans and experimentalanimals, Taurocholic acid irritates the gastric mucosa and causes the reversediffusion of acid through the broken barrier[3]. Specific Mmodeling Methods Rat: Donryu strain rats • male •230-240 g &bull Administration: 30-300 mg/kg • p.o • singledose. Note After rats have fasted for 24 hours, their pylorus is ligated under ether anesthesia. Fifteen minutes after pylorus ligation, medication is administered to the rats.The pylorus-ligated rats are then placed in cages with restricted movement.Subsequently, the cages are immersed in a water bath maintained at 23°C until the water level reaches the xiphoid process of the rats, lasting for 7 hours.Seven hours later, the animals are sacrificed under ether anesthesia, and the stomach of each animal is removed. The gastric contents are collected through the esophagus and analyzed for volume and acidity. Modeling Indicators Molecular Changes: Significant reductions in acidity and pepsin activity were observed, along with an increase in Na+ concentration. However, there was no effect on gastric juice volume or K+ concentration. Correlated Product(s): Aspirin (HY-14654) Opposite Product(s): L-Glutamine (HY-N0390)

IC50 & Target：Microbial Metabolite Human Endogenous Metabolite

Hot selling product：Enoxaparin  | Resorufin sodium salt  | 14-3-3 beta, Human  | 8-CPT-Cyclic AMP (sodium)  | KT203  | Tricin  | Enzastaurin  | BODIPY-FL  | PNGase F  | Proadifen (hydrochloride)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Mooranian A, et al. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015 Oct;5(5):511-22.  [Content Brief]

[2]. Xun Z,et al. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol. 2021 Feb;18(2):461-471.  [Content Brief]

[3]. Glaser S, et al. Taurocholic acid prevents biliary damage induced by hepatic artery ligation in cholestatic rats. Dig Liver Dis. 2010 Oct;42(10):709-17.  [Content Brief]